Table 1.
Demographics and Baseline Clinical Characteristics (Safety Population)
| Brensocatib (N = 49) | Placebo (N = 13) | |||||||
|---|---|---|---|---|---|---|---|---|
| 10 mg | 25 mg | 40 mg | ||||||
| Part A | Japanese (n = 8) | White (n = 8) | Japanese (n = 9) | White (n = 8) | Japanese (n = 8) | White (n = 8) | Japanese (n = 7) | White (n = 6) |
| Age, y, mean (SD) | 31.5 (6.8) | 39.5 (4.4) | 35.9 (7.3) | 37.4 (10.0) | 37.8 (5.7) | 37.4 (9.6) | 37.6 (7.3) | 43.7 (3.9) |
| Sex, n (%) | ||||||||
| Male | 6 (75.0) | 2 (25.0) | 2 (22.2) | 5 (62.5) | 5 (62.5) | 5 (62.5) | 2 (28.6) | 3 (50.0) |
| Female | 2 (25.0) | 6 (75.0) | 7 (77.8) | 3 (37.5) | 3 (37.5) | 3 (37.5) | 5 (71.4) | 3 (50.0) |
| Ethnicity, n (%) | ||||||||
| Hispanic | 0 | 4 (50.0) | 0 | 3 (37.5) | 0 | 5 (62.5) | 0 | 3 (50.0) |
| Non‐Hispanic | 8 (100) | 4 (50.0) | 9 (100) | 5 (62.5) | 8 (100) | 3 (37.5) | 7 (100) | 3 (50.0) |
| Height, cm, mean (SD) | 165.8 (7.6) | 165.3 (8.9) | 163.0 (8.2) | 173.3 (8.3) | 167.6 (9.4) | 168.1 (9.1) | 164.4 (10.4) | 167.0 (14.0) |
| Body weight, kg, mean (SD) | 62.4 (7.7) | 69.6 (8.4) | 57.8 (4.6) | 75.8 (9.3) | 67.6 (13.1) | 73.9 (14.1) | 62.4 (11.3) | 73.0 (8.8) |
| BMI, kg/m2, mean (SD) | 22.7 (2.2) | 25.5 (2.7) | 21.9 (2.6) | 25.2 (2.3) | 24.0 (3.3) | 26.0 (3.1) | 22.9 (2.7) | 26.3 (2.0) |
| Part B | Japanese (n = 10) | White (n = 10) | ||||||
|---|---|---|---|---|---|---|---|---|
| Age, y, mean (SD) | 35.0 (10.4) | 36.6 (9.6) | ||||||
| Sex, n (%) | ||||||||
| Male | 6 (60.0) | 7 (70.0) | ||||||
| Female | 4 (40.0) | 3 (30.0) | ||||||
| Ethnicity, n (%) | ||||||||
| Hispanic | 0 | 3 (30.0) | ||||||
| Non‐Hispanic | 10 (100.0) | 7 (70.0) | ||||||
| Height, cm, mean (SD) | 166.4 (7.6) | 171.4 (7.6) | ||||||
| Weight, kg, mean (SD) | 63.4 (11.3) | 73.9 (10.5) | ||||||
| BMI, kg/m2, mean (SD) | 22.8 (2.9) | 25.2 (3.6) |
BMI, body mass index.